Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?

Key Takeaways Rigel Pharmaceuticals expects 2025 sales to rise 60% to $232M, topping prior guidance.Tavalisse drove $158.9M in 2025 sales, up 52%, while Gavreto and Rezlidhia added momentum.RIGL guides 2026 product sales of $255-$265M but faces competition from Sanofi and Eli Lilly drugs.Rigel Pharmaceuticals (RIGL) had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven p ...